Sichuan Qingmu Pharmaceutical

VISIT THE VIRTUAL BOOTH, Contact Details

DIGITAL CONTENT

3 Corporate Content #SupplierSpotlight, 2 Data Compilation #PharmaFlow, 44 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

42 All APIs, 6 USDMF, 3 CEP/COS, 4 JDMF, 1 KDMF, 2 NDC API, 3 VMF, 42 Listed APIs

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

INTERMEDIATES

17 ALL Intermediates

17 ALL Intermediates

FINISHED DOSAGE FORMULATIONS

4 FDF Dossiers, 4 FDA Orange Book

KEY PRODUCTS

Firocoxib, Fruquintinib, Lemborexant, Maropitant, Oclacitinib Maleate

INSPECTIONS & REGISTRATIONS

2 FDA, 1 GDUFA

Filters

Digital content

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

Product List 2025

Open PDF

Upload

Intermediates Product List 2025

Open PDF

Upload

API Product List 2025

Open PDF

Upload

DATA COMPILATION #PharmaFlow

Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397 Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17 13 37 Taiwan 9 6 5 4 24 Switzerland 15 4 4 23 France 16 6 22 Japan 18 1 19 United Kingdom 12 1 2 15 Mexico 9 1 1 11 Ireland 5 5 1 11 Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years.

Impressions: 14230

DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024. Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each. The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders). View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453 US$ 3,21,920 Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427 US$ 2,31,952 FDF—Foreign US$ 2,35,427 US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629 US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852 US$ 7,56,666 Small business generic drug applicant US$ 1,72,963 US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.

Impressions: 8255

NEWS #PharmaBuzz

Lenvatinib Mesilate: Drug Interactions and Important Consideratio

29 May 2025

// PRESS RELEASE

The Difference Between Dabigatran Etexilate Mesylate and Pradaxa

18 Mar 2025

// PRESS RELEASE

The Impact of Sugammadex Sodium on the Autonomic Nervous System

17 Aug 2024

// PRESS RELEASE

Synthesis Methods of Lenvatinib Mesylate API

07 Aug 2024

// PRESS RELEASE

Sourcing Strategies for High-Quality Gadobutrol API

24 Jul 2024

// PRESS RELEASE

Quality Control in Parecoxib Sodium API Production

16 Jul 2024

// PRESS RELEASE

Contact Sichuan Qingmu Pharmaceutical and get a quotation

Sichuan Qingmu Pharmaceutical is a supplier offers 42 products (APIs, Excipients or Intermediates).

Find a price of Rotigotine bulk with DMF, CEP, JDMF offered by Sichuan Qingmu Pharmaceutical

Find a price of Bisoprolol Fumarate bulk with CEP, JDMF offered by Sichuan Qingmu Pharmaceutical

Find a price of Silodosin bulk with DMF, JDMF offered by Sichuan Qingmu Pharmaceutical

Find a price of Aprepitant bulk with CEP offered by Sichuan Qingmu Pharmaceutical

Find a price of Dabigatran Etexilate Mesylate bulk with DMF offered by Sichuan Qingmu Pharmaceutical

Find a price of Lenvatinib Mesylate bulk with DMF offered by Sichuan Qingmu Pharmaceutical

Find a price of Methylene Blue bulk with DMF offered by Sichuan Qingmu Pharmaceutical

Find a price of Sugammadex Sodium bulk with DMF offered by Sichuan Qingmu Pharmaceutical

Find a price of Ubenimex bulk with JDMF offered by Sichuan Qingmu Pharmaceutical

Find a price of Abemaciclib bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Afoxolaner bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Apatinib bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Axitinib bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Brexpiprazole bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Cabozantinib bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Darolutamide bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Diacerein bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Etoricoxib bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Firocoxib bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Fluralaner bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Fruquintinib bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Gadobutrol bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Grapiprant bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Ilunocitinib bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Ixazomib Citrate bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Lemborexant bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Lotilaner bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Lurbinectedin bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Maropitant bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Mianserin Hydrochloride bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Mirogabalin Besylate bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Nilotinib bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Niraparib Tosylate bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Oclacitinib Maleate bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Olanzapine bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Omadacycline bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Parecoxib Sodium bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Ponatinib bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Rabacfosadine bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Ruxolitinib Phosphate bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Sarolaner bulk offered by Sichuan Qingmu Pharmaceutical

Find a price of Vatinoxan Hydrochloride bulk offered by Sichuan Qingmu Pharmaceutical